The "European Inventor of the Year" award for 2009 was awarded to the scientists of the global pharmaceutical company "Novartis" for the development of the drugs "Gleevac" and "Quartem" which, according to the judges, changed the practice of the world of medicine
In the 'European Inventor of the Year' competition for 2009, the scientists of the global pharmaceutical company 'Novartis' who developed 'Glivec' and 'Coartem', life-saving drugs, won. At the awards ceremony held in Prague, the scientists won the title of 'European Invention of the Year' awarded by the European Commission and the European Patent Office.
The 'European Inventor of the Year' award recognizes those people who have contributed to the advancement of technology and the strengthening of the economy in Europe. The dedication, tenacity and expertise of the scientists, along with the collaboration with academic centers, turn the discovery and development of these kinds of inventions into medicines that have the power to save lives.
The awarding of the award demonstrates how the development of those scientists from Novartis changed the practice of medicine and thus improved the lives of patients around the world.
The Inventor's Award was awarded to two scientists from Novartis under the category known as 'Industry' for Haglivac, as a treatment for chronic myeloid leukemia (CML) and as a treatment for GIST type gastrointestinal cancer patients.
The 'Gleevec', which was developed in 2001, revolutionized the treatment option for cml patients and halting the deterioration of the disease, with regard to the treatment of GIST-type gastrointestinal cancer patients, this is a deadly cancer that is almost completely resistant to chemotherapy and radiation treatments. The 'Gleevec' reduces the risk of GIST cancer returning after surgery and turns the disease from fatal to treatable.
The Inventor's Award in the category that refers to an invention that was not developed on European soil was given to a Novartis development team located in China, for 'Quartem', a drug intended for the treatment of malaria, a disease that causes the death of about a million people a year, most of them children under the age of 5. In Africa alone, a child dies every 30 seconds from malaria.
The drug combines for the first time two active substances to treat the disease that were developed after patients on drugs based on one active substance developed resistance to the drug. In the clinical studies, the drug achieves over 95% cure of the disease. Since 2001, in a unique collaboration with the World Health Organization, Novartis has provided over 190 million treatments without profit to African countries. More recently, Novartis has developed Quartem in the form of sweet soluble tablets intended for the care of children.
3 תגובות
refresh
You probably live in your own world because there are trusted international organizations that finance (with donations) the treatments
these.
If you read to the end - you would see that it says:
"...in a unique collaboration with the World Health Organization, Novartis provided over 190 million treatments without profit to African countries..."
Well, then they invented the 'Quartem' that cures 95% of malaria cases, in Africa they will continue to die from malaria even if they invent a thousand more drugs that cure malaria. They don't have money for medicine, and no one will donate it to them for free, not even the UN, which doesn't even stop the Holocaust, so all the more it won't help with medicine in a significant way, (I say significantly, in order to distinguish it from giving medicines only in appearance, because The UN will probably make some kind of video showing the UN employees giving medicines to Africans, and the video is for PR purposes only of course)